CTSU CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma

February 06, 2010
Cancer - Genitourinary/ Bladder/ Prostate/ Urothel

Patients must have histologically documented metastatic or unresectable transitional cell carcinoma of the urinary tract (renal pelvis, ureter, bladder, prostate, or urethra), with progressive metatstatic or locally advanced disease (T4b, N2, N3, or M1); Patients must not be candidates for potentially curative surgery or radiotherapy; Patients may not have received combination systemic chemotherapy for metastatic disease.

Tiffany Pearce